Glaucoma Therapeutics Market -Regional Analysis
On the basis of region, GlaucomaTherapeutics Market is segmented into North America, Latin America, Europe,Middle East, Asia Pacific, and Africa. North America holds dominant position inglaucoma therapeutics market, followed by Asia Pacific. Increasing prevalenceof diabetes, increasing ocular disorders, and increasing number of blind andvisually impaired people in turn opting for glaucoma treatment are expected todrive growth of the glaucoma therapeutic market in these region. For instance,According to National Federation of the Blind, 2014, an estimated 10 millionpeople in the U.S. are blind or visually impaired. It is estimated that around1.3 million people are legally blind in the U.S. and the number is projected toincrease to 75,000 people annually in the U.S.
Asia Pacific is expected to gaina significant traction over the forecast period, owing to the governmentinitiatives and awareness programs to eliminate the blindness, which in turn ispropelling demand for glaucoma therapies in this region. For instance, in 2014,HelpAge India—a nonprofit organization—launched a special campaign to addressthe issue of blindness for underprivileged elderly populations of India.
However, strict regulationsconcerning marketing and approvals and the side effects of glaucoma medicationsare expected to hinder growth of the glaucoma therapeutic market in nearfuture. According to the Glaucoma Research Foundation, 2017 data findings, inthe U.S. use of alternative medicines for the treatment of glaucoma hasincreased 10% to 15% in the past ten years. Furthermore, according to the samesource, 50% of the glaucoma patients in the U.S. use some form of alternativetherapy in 2017.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1675
Glaucoma refers to the group ofconditions characterized by optic nerve damage, visual field loss, andsecondary to retinal ganglion cell damage, which may lead to death. Accordingto the International Agency for the Prevention of Blindness: 2017, glaucoma issecond leading cause of blindness and leading cause of irreversible blindnessworldwide. The most common types of glaucoma are Primary Open Angle Glaucoma(POAG) and Primary Angle Closure Glaucoma (PACG). Moreover, PACG is most commonin South-East Asian population while POAG is most common in white Caucasiansand individuals of African origin. PACG is associated with a high risk ofblindness as compared to POAG.
Glaucoma Therapeutics MarketDrivers
Increasing number of patientswith glaucoma and increasing incidences of blindness are expected to be themajor driving factor for growth of the global glaucoma therapeutics market.According to the International Agency for the Prevention of Blindness, 2010data findings, it is estimated that by 2020, around 80 million people willsuffer from glaucoma, with an increase of about 20 million form 2010.Furthermore, in 2010, over 8 million people were bilaterally blind due toglaucoma, which is expected to increase to over 11 million by 2020. Thesignificant risk of developing glaucoma increases with geriatric population,increased intraocular pressure, positive family history for glaucoma, andethnicity. According to the American Academy of Ophthalmology (AAO), 2016: theglobal prevalence of glaucoma is estimated to rise to 76 million in 2020 and111.8 million in 2040.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/glaucoma-therapeutics-market-1675
Glaucoma may occur among thepeople with or without diabetes. Moreover, people with diabetic retinopathyhave an increased risk of glaucoma. The condition is associated with abnormalblood vessel growth, which can result in retinopathy and leads to blockage ofnatural drainage of the eye. Rapidly increasing geriatric population is one ofthe important factors for increasing prevalence of glaucoma, which in turn isprojected to drive growth of the glaucoma therapeutics market in near future.For instance, according to the International Diabetes Foundation (IDF) 2017statistics, the number of people with diabetes aged between 20 to 79 years areincreasing worldwide. Among which, Africa (156%) is accounted to register thehighest diabetic population, followed by Middle East (110%), South East Asia(84%), Latin and Central America(62%), North America (35%), Europe (16%), andWestern Pacific (15%).
Glaucoma Therapeutics MarketCompetitive Landscape
Some of the key players operatingin the glaucoma therapeutics market include Valeant PharmaceuticalsInternational, Inc., Allergan Inc., Merck KGaA, Fera Pharmaceuticals, LLC, TevaPharmaceutical Industries Ltd., Pfizer Inc., Aristo Pharmaceuticals Pvt. Ltd.,Santen Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, and Novartis AG. Keyplayers in the market are focusing on organic growth strategies in order togain maximum market share and retain leading position in the market. Forinstance, in December 2017, Aerie Pharmaceuticals, Inc. received the U.S. Foodand Drug Administration (FDA) approval for Rhopressa (netarsudil ophthalmicsolution) 0.02%, indicated for lowering of elevated intraocular pressure (IOP)in patients with open-angle glaucoma or ocular hypertension.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1675
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
Coherent MarketInsights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
